coin-img-ETHETH+0.44%coin-img-SOLSOL-2.37%coin-img-BTCBTC-0.87%coin-img-XRPXRP-0.90%coin-img-ONDOONDO-7.41%coin-img-ZECZEC-7.11%coin-img-PSRMMPSRMM+0.00%coin-img-USDCUSDC+0.03%coin-img-ETHETH+0.44%coin-img-SOLSOL-2.37%coin-img-BTCBTC-0.87%coin-img-XRPXRP-0.90%coin-img-ONDOONDO-7.41%coin-img-ZECZEC-7.11%coin-img-PSRMMPSRMM+0.00%coin-img-USDCUSDC+0.03%coin-img-ETHETH+0.44%coin-img-SOLSOL-2.37%coin-img-BTCBTC-0.87%coin-img-XRPXRP-0.90%coin-img-ONDOONDO-7.41%coin-img-ZECZEC-7.11%coin-img-PSRMMPSRMM+0.00%coin-img-USDCUSDC+0.03%coin-img-ETHETH+0.44%coin-img-SOLSOL-2.37%coin-img-BTCBTC-0.87%coin-img-XRPXRP-0.90%coin-img-ONDOONDO-7.41%coin-img-ZECZEC-7.11%coin-img-PSRMMPSRMM+0.00%coin-img-USDCUSDC+0.03%
user-avatar
Barron's

Kodiak Sciences shares jump 183% after Zenkuda wet AMD trial succeeds, setting up filing against Regeneron’s Eylea

AI Market Summary
Kodiak Sciences reported successful clinical trial results for its wet AMD candidate Zenkuda and plans to submit for regulatory approval, triggering a 183% one-day surge in its shares. The readout increases perceived competitive pressure on Regeneron's Eylea franchise and can drive near-term repricing across ophthalmology-focused biotech and related large-cap exposure as investors reassess market share and pipeline risk.
Impact level
● Medium
Affected assets
NCSKCRDO2USD/USDT-8.19%
AI Insight · NCSKCRDO2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Kodiak Sciences said its wet age-related macular degeneration drug candidate Zenkuda met its clinical trial goals, clearing the way for a regulatory submission. The company said it plans to file the treatment for approval. The update sent Kodiak’s shares up 183% in a single session. Zenkuda is positioned to compete directly with Regeneron’s blockbuster Eylea, drawing heightened investor attention.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.